Pharmacokinetics of Tasimelteon Alone and in Combination With CYP1A2 Inhibitor, Fluvoxamine
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this research study is to evaluate whether administration of a CYP1A2
inhibitor affects the single-dose pharmacokinetics of tasimelteon and its metabolites. The
safety and tolerability of tasimelteon will also be assessed throughout the study.